CCM
KPTI icon

Context Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Context Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,995
Closed -$464K – 395
2025
Q4 		$464K Buy
+62,995
New +$385K 0.01% 199

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Context Capital Management's KPTI Position: Q1 2026 in Review

Context Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 62,995 shares — an estimated $464K sold.

Context Capital Management first reported a position in KPTI in Q4 2025 and held it in 1 quarter. The position peaked at $464K in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Context Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Context Capital Management sold 62,995 Karyopharm Therapeutics shares in Q1 2026, an estimated $464K.
  • Context Capital Management first reported a position in Karyopharm Therapeutics in Q4 2025 and held it in 1 quarter.
  • Context Capital Management's Karyopharm Therapeutics position peaked at $464K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Context Capital Management's 13F filing for Q1 2026, filed 7 May 2026.